Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Recs

0
Player Avatar investat (< 20) Submitted: 5/31/2011 10:21:29 AM : Outperform Start Price: $8.10 CRTX Score: -33.60

Projective Target Price: $29.56

Featured Broker Partners


Advertisement